Abstracts from the 21st International Congress on Thrombosis
The Start of a New Era for Antithrombotic Agents

Milan, Italy, July 6–9, 2010

Guest Editor
P.M. Mannucci, Milan, Italy
This publication has been produced by the Organizers of the 21st International Congress on Thrombosis
## Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>XII</td>
<td>Foreword</td>
</tr>
<tr>
<td></td>
<td><strong>Plenary Lectures</strong></td>
</tr>
</tbody>
</table>
| P1   | Discovery of drugs in haemostasis and thrombosis by serendipity  
M.M. Samama, France |
| P2   | New targets in cardiovascular prevention: the identification of specific disease mechanisms  
A. Maseri, Italy |
|      | **Opening Symposium** |
|      | **Air pollution and thrombosis** |
| P5   | Air pollution, blood clotting and cardiovascular disease: evidence from epidemiological studies and impact on the population  
A. Peters, Germany |
| P6   | Beyond the DNA sequence: epigenetic mechanisms of prothrombotic air pollution effects  
A. Baccarelli, Italy |
| P7   | Inhaled particles and thrombosis: a clinical toxicology perspective  
N.L. Mills, UK |
|      | **Morning Lectures** |
| P11  | Hypercoagulability and thrombosis in sickle cell anemia and thalassemia  
D. Varon, Israel |
| P12  | Inflammation and atherothrombosis  
E. Stroes, the Netherlands |
| P13  | Leukocytosis as a thrombosis risk factor  
T. Barbui, Italy |
| P15  | Familial thrombophilia without a positive laboratory screening  
J. Conard, France |
| P16  | Haemotransfusion in coronary heart disease: friend or foe?  
M. Lettino, Italy |
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P17</td>
<td>New antiplatelet agents: why they are badly needed by the cardiologist</td>
<td>P. A. Merlini, Italy</td>
</tr>
<tr>
<td>P18</td>
<td>Is aspirin less effective in patients with diabetes?</td>
<td>S. Coccheri, Italy</td>
</tr>
<tr>
<td>P19</td>
<td>Which antithrombotic and antiplatelet therapies in the ambulance for acute coronary syndrome?</td>
<td>M. Tubaro, Italy</td>
</tr>
<tr>
<td>P20</td>
<td>Biomarkers for the diagnosis of venous thromboembolism</td>
<td>A. Perrier, Switzerland</td>
</tr>
<tr>
<td>P21</td>
<td>Cerebral vein thrombosis</td>
<td>J. Ferro, Portugal</td>
</tr>
<tr>
<td>P22</td>
<td>Moderate hyperhomocysteinemia: marker or cause of a disease?</td>
<td>R. Abbate, Italy</td>
</tr>
<tr>
<td>P23</td>
<td>Pharmacoepidemiology of gastrointestinal bleeding complications of antiplatelet agents</td>
<td>A. Lanas, Spain</td>
</tr>
<tr>
<td>P24</td>
<td>Antithrombotic agents after vascular surgery</td>
<td>D. Bergqvist, Sweden</td>
</tr>
<tr>
<td>P25</td>
<td>What is new on the clinical aspects of fibrinolysis and thrombolysis?</td>
<td>J.A Páramo, Spain</td>
</tr>
<tr>
<td>P26</td>
<td>Thromboprophylaxis in 'minor' orthopedic surgery</td>
<td>H. Bounameaux, Switzerland</td>
</tr>
<tr>
<td>P27</td>
<td>Highlights of the 5th International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2010</td>
<td>A. Falanga, Italy</td>
</tr>
<tr>
<td>P28</td>
<td>A renaissance of the contact phase of blood coagulation</td>
<td>U. Seligsohn, Israel</td>
</tr>
<tr>
<td>P29</td>
<td>News on the anticoagulant pathway of blood coagulation</td>
<td>J. Corral, Spain</td>
</tr>
</tbody>
</table>

**Debates**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P32</td>
<td>Is it clinically useful to extend to the calf the ultrasound examination of deep leg veins? Yes/No</td>
<td>S.M. Schellong (Germany) vs G. Palaret (Italy)</td>
</tr>
<tr>
<td>P34</td>
<td>Variable antiplatelet response to thienopyridines: should we use lab tests? Yes/No</td>
<td>J.F. Collet (France) vs B. Rocca (Italy)</td>
</tr>
<tr>
<td>P36</td>
<td>Thromboembolic pulmonary hypertension (CTEPH). Early surgery or watchful waiting?</td>
<td>A.M. D’Armini (Italy) vs F. Piovella (Italy)</td>
</tr>
</tbody>
</table>
Lectures

P41  Role of statins and exercise on vulnerable plaques  
     C. Liapis, Greece

P42  Thrombosis in neonates and children:  
     What do we know - where to go?  
     U. Nowack-Göttl, Germany

P43  Adjunctive antithrombotic agents to amplify 
     thrombolysis in ischemic stroke  
     J. Grotta, USA

P44  Discovery of quantitative traits loci 
     for platelets  
     W. Ouwehand, UK

P45  The future of anticoagulant therapy  
     G. Agnelli, Italy

P46  The role of tissue factor in coronary 
     artery disease  
     T.F Lüscher, Switzerland

Joint Symposium

Grupo Cooperativo Latinoamericano de Hemostasia y 
Trombosis (CLAHT) and Mediterranean League Against 
Thromboembolic Diseases (MLTD)

Advances in thrombosis

P49  What is new on the antiphospholipid syndrome criteria  
     R. Forastiero, Argentina

P50  Thrombotic complications in the treatment 
     of patients with bleeding disorders  
     M. Mijares, Venezuela

P51  A multicentre randomised study of computer-assisted 
     oral anticoagulant dosage versus medical staff dosage  
     L. Poller, UK

P52  Thrombosis prophylaxis in the ambulatory cancer 
     patient: approaches to identifying the high risk patient  
     K. Bauer, USA

Symposia

Venous thromboembolism (VTE) in special 
clinical conditions: natural history

P53  Hormonal contraceptives, hormone-replacement 
     therapy and thromboembolism  
     B. Brenner, Israel

P54  Venous thromboembolism (VTE) in the very elderly  
     A. Leizorovicz, France

P55  Venous thromboembolism (VTE) in the very young  
     M. Monreal, Spain
Advances in peripheral arterial disease

P56 Peripheral arterial disease in the spectrum of atherothrombosis
G.D.O. Lowe, UK

P57 Asymptomatic peripheral arterial disease: impact on clinical practice
F. Violi, Italy

P58 Antiplatelet treatment
G. Y. Lip, UK

Genomewide association studies

P59 Stroke
M. Breteler, the Netherlands

P60 Lessons from genome wide association studies in venous thrombosis
P. Morange, France

P61 Mapping genes for plasma lipids and myocardial infarction in humans
S. Kathiresan, USA

New anticoagulants: highlights on methodological issues

P62 Lack of standardization between antithrombotic trials in orthopedics: the scenario
O.E. Dahl, Norway

P63 Methodological issues in trials assessing primary prophylaxis of venous thromboembolism
C.M. Samama, France

P64 Make clinical studies in medical patients closer to usual hospital care
J. Harenberg, Germany

P65 Guidelines on clinical testing of new antithrombotic drugs in surgical patients
A.K. Kakkar, UK

Therapeutic advances in stroke

P66 Thrombolysis in acute stroke: present evidences and future perspectives
D. Toni, Italy

P67 Secondary prevention of cerebral ischemia of arterial origin
A. Algra, the Netherlands

P68 Secondary prevention of cardioembolic stroke: old and new drugs
J. Ferro, Portugal

Platelets and inflammation

P69 Platelets and atherosclerosis
M. Gawaz, Germany
Platelets and allergic disorders
P. Gresele, Italy

Platelets, inflammation and acute coronary syndrome
L. Badimon, Spain

Venous and arterial thromboembolism: an overlapping risk

Clinical VTE and subsequent risk of arterial thrombotic events in non-provoked populations
G.D.O. Lowe, UK

Surgical triggering of venous and arterial thromboembolism: Immediate and long-term consequences
O.E. Dahl, Norway

Pregnancy and obstetric complications and the link to venous and arterial thrombosis
I. Greer, UK

Special problems and strategies in anticoagulation

Bridging strategies for interruption of anticoagulation for invasive procedures
S. Schulman, Canada

Antisense anticoagulant treatment
M. Levi, the Netherlands

Anticoagulant and thrombolytic treatment of portal vein and digestive tract thrombosis
F. Leebeek, the Netherlands

Atrial fibrillation and heart failure as thrombotic disorders

Atrial fibrillation as a thrombotic disease
G. Y. Lip, UK

Heart failure and thrombotic complications
C. Torp-Pedersen, Denmark

Heart failure as a prothrombotic state
P.W. Kamphuisen, the Netherlands

The benefits and risks of low-dose aspirin in primary prevention of atherothrombosis

Should aspirin be used for the primary prevention of vascular disease?
C. Baigent, UK

Aspirin for people with diabetes: current evidence and ongoing trials.
J. Armitage, UK

Ongoing trials on aspirin for primary prevention: will they deliver?
G. Tognoni, Italy
Long-term complications of venous thromboembolism

P85  The optimal duration of anticoagulant therapy in patients with venous thromboembolism
P. Prandoni, Italy

P86  Long-term complications of venous thromboembolism
S. Kahn, Canada

P87  Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension
I. Lang, Austria

Dietary habits and cardiovascular risk

P88  Is the evidence from observational studies sufficient to state that Mediterranean diet reduces CV risk?
A. Kafatos, Greece

P89  Alcohol and cardiovascular risk: is there a window for benefits?
A. Di Castelnuovo, Italy

P90  Food and health: is inflammation the round-about?
H. Schröder, Spain

Satellite

Thrombotic microangiopathies

P93  The genetic base of congenital thrombotic thrombocytopenic purpura (TTP)
F. Peyvandi, Italy

P94  New therapies in acquired TTP
M. Scully, UK

P95  New diagnostic and prognostic aspects of acquired TTP
J. Kremer-Hovinga, Switzerland

P96  Rethinking thrombotic microangiopathies
G. Remuzzi, Italy

New perspectives in thrombosis research

P97  Complete deficiency of ADAMTS13 is sufficient to cause TTP in non-human primates
H.B. Feys, N. Vandeputte, J. Roodt, S. Lamprecht, W.J. van Rensburg, V.J. Louw, P.N. Badenhorst, H. Deckmyn, K. Vanhoorelbeke, Belgium and South Africa

P98  Aspirin resistance: myth or reality?

P99  Environment and life style: can they affect the response to antiplatelet agents?
G. de Gaetano, C. Cerletti, Italy

P100  Arterial thrombosis in antiphospholipid syndrome
J. Musial, J. Swadzba, A. Matyja-Bednarczyk, T. Iwaniec, Poland
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P101</td>
<td>The epidemiology of venous thromboembolism and experience with its management in Italy</td>
<td>W. Ageno</td>
<td>Italy</td>
</tr>
<tr>
<td>P102</td>
<td>The burden of venous thromboembolism in the hospital setting</td>
<td>A.T. Cohen</td>
<td>UK</td>
</tr>
<tr>
<td>P104</td>
<td>What can ongoing clinical trials of anticoagulants demonstrate?</td>
<td>H.R. Büller</td>
<td>the Netherlands</td>
</tr>
<tr>
<td>P105</td>
<td>Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement: the RECORD study program</td>
<td>L. Borris</td>
<td>Denmark</td>
</tr>
</tbody>
</table>

**Thrombosis and antithrombotic therapy: what have we learnt in the low-molecular-weight heparin era?**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P106</td>
<td>Thrombosis and antithrombotic therapy: how we currently use LMWHs</td>
<td>A.K. Kakkar</td>
<td>UK</td>
</tr>
<tr>
<td>P107</td>
<td>Recommendations for the preparation of biosimilar LMWHs according the ISTH SSC compared to FDA and EMEA views</td>
<td>J. Harenberg</td>
<td>Germany</td>
</tr>
<tr>
<td>P108</td>
<td>Biostatistical requirements for development of biosimilar LMWHs</td>
<td>P. Mismetti</td>
<td>France</td>
</tr>
</tbody>
</table>

**Xa inhibition in the whole spectrum of venous thromboembolism: new insights**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P109</td>
<td>Superficial vein thrombosis (SVT): recent epidemiology data</td>
<td>A. Leizorovicz</td>
<td>France</td>
</tr>
<tr>
<td>P110</td>
<td>Pharmacological treatment of SVT: what is the evidence?</td>
<td>H. Decousus</td>
<td>France</td>
</tr>
<tr>
<td>P111</td>
<td>Pharmacological management of deep vein thrombosis and pulmonary embolism</td>
<td>H.R. Büller</td>
<td>Netherlands</td>
</tr>
<tr>
<td>P112</td>
<td>SVT management guidelines</td>
<td>K. Bauer</td>
<td>USA</td>
</tr>
</tbody>
</table>

**Heparin induced thrombocytopenia (HIT): diagnosis and treatment**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author(s)</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P113</td>
<td>HIT: pathophysiology, incidence and guidelines</td>
<td>A. Greinacher</td>
<td>Germany</td>
</tr>
<tr>
<td>P114</td>
<td>Laboratory aspects in HIT diagnosis: current status</td>
<td>I. Elalamy</td>
<td>France</td>
</tr>
</tbody>
</table>
Transforming the management of venous and arterial thrombosis

P116 Venous and arterial thromboembolism: the causes and consequences
W. Ageno, Italy

P117 Primary prevention of VTE after hip or knee arthroplasty - experience with dabigatran etexilate
B.I. Eriksson, Sweden

P118 New developments in the treatment of acute VTE
P. Mismetti, France

P119 Stroke prevention in atrial fibrillation – changing the paradigm?
R. de Caterina, Italy

Advancing the field of anticoagulation: oral factor Xa inhibitors

P120 Pharmacology of the new oral anticoagulants
J.W.A. Eikelboom, Canada

P121 Recent trials of oral factor Xa inhibitors in orthopaedic surgery
M.R. Lassen, Denmark

P122 Future perspectives in oral anticoagulation
R. de Caterina, Italy

Focus on thrombin receptor antagonists as antiplatelet agents

P123 Limitations of currently available antiplatelet drugs
C. Patrono, Italy

P124 Thrombin receptor antagonist as a novel approach for the treatment of atherothrombosis
G. Ambrosio, Italy

The use of LMWHs in special clinical settings

P125 Extension of thromboprophylaxis after surgery for cancer
P. Prandoni, Italy

P126 Management of LMWHs in renal impairment and elderly patients
S. Rico, Spain

P127 Prevention of VTE during pregnancy
A. Santamaria Ortiz, Spain

P128 Optimizing antiplatelet therapy: insight from large outcomes trials
D. Ardissino, Italy
P130  High on-treatment platelet reactivity as a risk factor for stent thrombosis
N.J. Breet, C.H. Hackeng, the Netherlands

Oral Presentations
A1  Pulmonary embolism
A2  Pregnancy and thrombosis
A4  Hematological disorders and thrombosis
A6  Mechanisms of Thrombosis 1
A8  Coronary artery disease
A10 New anticoagulants 1
A12 Clinical aspects of venous thromboembolism 1
A14 Thrombosis issues in internal medicine 1
A15 Ischemic stroke / atrial fibrillation
A17 Mechanisms of thrombosis 2
A19 New anticoagulants 2
A21 New and old predictors of venous thromboembolism
A23 Thrombosis issues in internal medicine and pediatrics 2
A24 Inherited Thrombophilia
A26 Clinical aspects of venous thromboembolism 2

Posters
A29  Clinical aspects of thrombosis
A42  Diagnostic and laboratory methods in thrombosis
A55  Inherited and acquired thrombophilia
A64  Cerebrovascular and peripheral atherothrombosis
A75  Pregnancy, hormones and thrombosis
A83  Mechanisms of thrombosis
A93  New anticoagulants
A100 Fibrinolysis and thrombolysis
A103 Cancer and thrombosis
A109 Atrial fibrillation
A111 Miscellanea
A115 Thrombosis risk factors
A126 Coronary artery disease
A133 Traditional anticoagulants
A145 Antiplatelet agents
A151 Hematological disorders and thrombosis
A159  Read by Title
A179  Index of Authors
Pathophysiology of Haemostasis and Thrombosis

Foreword

Pier Mannuccio Mannucci

Together with the members of the various Committees that have tremendously helped me (Executive Committee, International Committee, Advisory Committee and the Mediterranean League Council), I present you this Supplement of Pathophysiology of Thrombosis and Haemostasis, which contains the abstracts of the 21st International Thrombosis Congress, which I am organizing on behalf of the Mediterranean League against Thromboembolic Diseases.

I must admit that our main problem was one of abundance. We received as many as 643 submitted abstracts from 57 countries and the 5 continents: a record in the history of the MLTD Congresses! This abundance was not anticipated (only 255 abstracts were submitted for the 20th Congress in Athens two years ago). Hence, we have originally allotted a too limited space to oral communications and posters, by giving most of the space to invited Symposia, Lectures and Debates.

Each submitted abstract was evaluated by at least 3 reviewers and their ranking was the basis for the choice of their presentation as oral communications (only 14%) or poster.

Having said this as a preamble, we hope that this Book of Abstracts is satisfactory. The main topics are the new anticoagulant and antiplatelet agents, and venous thromboembolism prevails among the three most frequent thromboembolic diseases, even though coronary artery and cerebrovascular diseases are also well featured in the abstracts.

The Satellite events organized in collaboration with the pharmaceutical industry feature new drugs and new reagents and contribute substantially to the scientific quality of this publication, at this time of rapidly expanding availability of new weapons in the fight against thrombosis.

Finally, I want to express my thanks and gratitude to Silvia Malosio and Viviana Quaroni, who did a monumental job in collecting the abstracts published in this Supplement of Pathophysiology of Haemostasis and Thrombosis, the official Journal of the League.

Pier Mannuccio Mannucci
Guest Editor